The collaborative cross strains and their founders vary widely in cocaine-induced behavioral sensitization.

cocaine collaborative cross genetics heritability inbred mice sensitization

Journal

Frontiers in behavioral neuroscience
ISSN: 1662-5153
Titre abrégé: Front Behav Neurosci
Pays: Switzerland
ID NLM: 101477952

Informations de publication

Date de publication:
2022
Historique:
received: 28 02 2022
accepted: 01 08 2022
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 25 10 2022
Statut: epublish

Résumé

Cocaine use and overdose deaths attributed to cocaine have increased significantly in the United States in the last 10 years. Despite the prevalence of cocaine use disorder (CUD) and the personal and societal problems it presents, there are currently no approved pharmaceutical treatments. The absence of treatment options is due, in part, to our lack of knowledge about the etiology of CUDs. There is ample evidence that genetics plays a role in increasing CUD risk but thus far, very few risk genes have been identified in human studies. Genetic studies in mice have been extremely useful for identifying genetic loci and genes, but have been limited to very few genetic backgrounds, leaving substantial phenotypic, and genetic diversity unexplored. Herein we report the measurement of cocaine-induced behavioral sensitization using a 19-day protocol that captures baseline locomotor activity, initial locomotor response to an acute exposure to cocaine and locomotor sensitization across 5 exposures to the drug. These behaviors were measured in 51 genetically diverse Collaborative Cross (CC) strains along with their inbred founder strains. The CC was generated by crossing eight genetically diverse inbred strains such that each inbred CC strain has genetic contributions from each of the founder strains. Inbred CC mice are infinitely reproducible and provide a stable, yet diverse genetic platform on which to study the genetic architecture and genetic correlations among phenotypes. We have identified significant differences in cocaine locomotor sensitivity and behavioral sensitization across the panel of CC strains and their founders. We have established relationships among cocaine sensitization behaviors and identified extreme responding strains that can be used in future studies aimed at understanding the genetic, biological, and pharmacological mechanisms that drive addiction-related behaviors. Finally, we have determined that these behaviors exhibit relatively robust heritability making them amenable to future genetic mapping studies to identify addiction risk genes and genetic pathways that can be studied as potential targets for the development of novel therapeutics.

Identifiants

pubmed: 36275853
doi: 10.3389/fnbeh.2022.886524
pmc: PMC9580558
doi:

Types de publication

Journal Article

Langues

eng

Pagination

886524

Informations de copyright

Copyright © 2022 Schoenrock, Gagnon, Olson, Leonardo, Philip, He, Reinholdt, Sukoff Rizzo, Jentsch, Chesler and Tarantino.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Neurosci. 2001 Dec;4(12):1217-23
pubmed: 11694884
Nat Rev Genet. 2005 Jul;6(7):521-32
pubmed: 15995696
Trends Neurosci. 2010 Jun;33(6):267-76
pubmed: 20207024
Pharmacogenetics. 2001 Apr;11(3):255-64
pubmed: 11337941
Genes Brain Behav. 2008 Nov;7(8):859-68
pubmed: 19076633
Neurosci Biobehav Rev. 2013 Sep;37(8):1738-53
pubmed: 23850581
Explor Med. 2021;2:60-73
pubmed: 34124712
J Neural Transm (Vienna). 2019 Apr;126(4):481-516
pubmed: 30569209
Genetics. 2012 Feb;190(2):291-4
pubmed: 22345604
G3 (Bethesda). 2014 Sep 18;4(9):1623-33
pubmed: 25237114
Exp Clin Psychopharmacol. 2011 Oct;19(5):321-41
pubmed: 21843010
Addict Biol. 2022 May;27(3):e13162
pubmed: 35470554
Pharmacol Biochem Behav. 2010 Mar;95(1):63-71
pubmed: 20006968
Philos Trans R Soc Lond B Biol Sci. 2008 Oct 12;363(1507):3137-46
pubmed: 18640920
Brain Res Brain Res Rev. 1997 Oct;25(2):192-216
pubmed: 9403138
Genes Brain Behav. 2021 Nov;20(8):e12773
pubmed: 34672075
Crit Rev Neurobiol. 2005;17(2):69-86
pubmed: 16808728
Drug Alcohol Depend. 2017 Nov 1;180:376-384
pubmed: 28961544
Psychopharmacology (Berl). 1995 Dec;122(3):209-14
pubmed: 8748389
Psychopharmacology (Berl). 2009 Dec;207(2):325-34
pubmed: 19774366
J Vis Exp. 2016 Feb 18;(108):53107
pubmed: 26967472
MMWR Morb Mortal Wkly Rep. 2019 May 03;68(17):388-395
pubmed: 31048676
J Addict Dis. 2001;20(3):43-54
pubmed: 11681592
Psychopharmacology (Berl). 2018 Apr;235(4):1179-1189
pubmed: 29423710
Psychopharmacology (Berl). 2016 Feb;233(4):701-14
pubmed: 26581503
Science. 2013 Dec 20;342(6165):1508-12
pubmed: 24357318
Psychopharmacology (Berl). 1991;103(4):480-92
pubmed: 2062986
Brain Res Brain Res Rev. 1991 Sep-Dec;16(3):223-44
pubmed: 1665095
Trends Genet. 2019 Jul;35(7):501-514
pubmed: 31133439
Addiction. 2018 Oct;113(10):1905-1926
pubmed: 29749059
Psychopharmacology (Berl). 1994 Jun;115(1-2):265-72
pubmed: 7862906
Psychiatr Clin North Am. 2012 Jun;35(2):495-519
pubmed: 22640768
Br J Pharmacol. 2008 May;154(2):327-42
pubmed: 18345022
J Neurosci. 2002 Jun 1;22(11):4654-62
pubmed: 12040071
Neurosci Biobehav Rev. 2018 Apr;87:218-232
pubmed: 29357292
Brain Res. 1993 Oct 1;623(2):341-4
pubmed: 8221119
Psychopharmacology (Berl). 2020 Apr;237(4):979-996
pubmed: 31897574
Pharmacogenetics. 1999 Oct;9(5):607-17
pubmed: 10591541
Brain Res. 1990 Apr 23;514(1):22-6
pubmed: 2357527
ACS Chem Neurosci. 2019 Jul 17;10(7):3053-3060
pubmed: 30817127
Eur J Neurosci. 2003 Feb;17(3):590-6
pubmed: 12581176
J Pharmacol Exp Ther. 1994 Sep;270(3):1230-8
pubmed: 7932176
Psychopharmacology (Berl). 1996 Apr;124(3):279-81
pubmed: 8740051
Pharmacol Biochem Behav. 2000 Aug;66(4):765-70
pubmed: 10973514
Ann N Y Acad Sci. 2014 Oct;1327:1-26
pubmed: 24654857
Pharmacogenetics. 2003 Jun;13(6):329-38
pubmed: 12777963
Neurosci Biobehav Rev. 2012 Jul;36(6):1565-76
pubmed: 22542906
Genes Brain Behav. 2015 Mar;14(3):271-80
pubmed: 25727211
Science. 1999 Jun 4;284(5420):1670-2
pubmed: 10356397
Pharmacol Biochem Behav. 1990 Dec;37(4):707-11
pubmed: 2093176
Nat Rev Neurosci. 2011 Oct 12;12(11):623-37
pubmed: 21989194
Mamm Genome. 2014 Apr;25(3-4):95-108
pubmed: 24487921
Psychopharmacology (Berl). 2000 Aug;151(2-3):99-120
pubmed: 10972458
J Heart Lung Transplant. 2019 Feb;38(2):194-202
pubmed: 30522722
Eur J Neurosci. 1998 Nov;10(11):3565-71
pubmed: 9824469
J Neurosci. 1998 Apr 15;18(8):3023-34
pubmed: 9526019
mBio. 2015 May 05;6(3):e00493-15
pubmed: 25944860
Mol Psychiatry. 2014 Jun;19(6):717-23
pubmed: 23958962
Pharmacol Rev. 2011 Jun;63(2):348-65
pubmed: 21490129
Neuropharmacology. 2014 Jan;76 Pt B:204-17
pubmed: 24035914
J Psychiatry Neurosci. 2019 Sep 06;45(1):34-44
pubmed: 31490055

Auteurs

Sarah A Schoenrock (SA)

Department of Genetics, School of Medicine, Chapel Hill, NC, United States.
Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.

Leona Gagnon (L)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.

Ashley Olson (A)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.

Michael Leonardo (M)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.

Vivek M Philip (VM)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.

Hao He (H)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.

Laura G Reinholdt (LG)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.

Stacey J Sukoff Rizzo (SJ)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.
Department of Medicine, University of Pittsburgh, Pittsburgh, PA, United States.

James D Jentsch (JD)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
Department of Psychology, Binghamton University, Binghamton, NY, United States.

Elissa J Chesler (EJ)

Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
The Jackson Laboratory, Bar Harbor, ME, United States.

Lisa M Tarantino (LM)

Department of Genetics, School of Medicine, Chapel Hill, NC, United States.
Center for Systems Neurogenetics of Addiction, Bar Harbor, ME, United States.
Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.

Classifications MeSH